Showing results (21-30 of 128) with videos related to
Sort By:
Pageof 13
Journal of Blood Medicine|April 21, 2020
Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell TransplantationUmberto Restelli, Davide Croce, Erminio Bonizzoni, et al.Plos One|March 6, 2013
Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldEmanuela Foglia, Paolo Bonfanti, Giuliano Rizzardini, et al.BMJ Open|August 3, 2017
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in ItalyUmberto Restelli, Gabriella Saibene, Patrizia Nardulli, et al.Clinicoeconomics and Outcomes Research : CEOR|October 7, 2014
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceUmberto Restelli, Massimo Andreoni, Andrea Antinori, et al.Insights Into Imaging|February 25, 2014
Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessmentGiovanni Mauri, Emanuele Porazzi, Luca Cova, et al.The New Microbiologica|September 3, 2014
Health technology assessment in the HIV setting: the case of monotherapyUmberto Restelli, Davide Croce, Emanuele Porazzi, et al.BMJ Open|September 14, 2019
Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysisUmberto Restelli, Marzia Bonfanti, Davide Croce, et al.Journal of Blood Medicine|January 16, 2019
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective surveyRolando Innocenti, Luigi Rigacci, Umberto Restelli, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 7, 2011
The cost of HIV disease in Northern Italy: the payer's perspectiveGiuliano Rizzardini, Umberto Restelli, Paolo Bonfanti, et al.Multidisciplinary Respiratory Medicine|April 8, 2025
The role of Fraction Exhaled Nitric Oxide (FeNO) in asthma management: an Italian consensus statement on clinical and economic aspectsMatteo Bonini, Rosa Annibale, Simona Barbaglia, et al.Pageof 13